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Summary
The Fos protein, a major component of the AP-1 transcription factor, is essential for osteoclast differentiation, acts as an
oncogene, potentiates transforming signals, and controls invasive growth and angiogenesis during tumor progression. To
investigate a potential genetic interaction between the Trp53 and Fos pathways, Trp53/Fos double knockout mice were
generated. These mice develop highly proliferative and invasive rhabdomyosarcomas of the facial and orbital regions, with
more than 90% penetrance at 6 months of age. Rhabdomyosarcoma cell lines established from the primary tumors express
characteristic muscle-specific markers, and reexpression of Fos is associated with enhanced apoptosis in vitro. Moreover,
Fos is able to repress Pax7 expression in rhabdomyosarcoma cell lines and primary myoblasts, suggesting a molecular
link to genetic alterations involved in human rhabdomyosarcomas.
Introduction tion factor, which regulates various biological processes by con-
verting extracellular signals into changes in the expression of
specific target genes (Jochum et al., 2001). Mice lacking FosRhabdomyosarcoma is the most common soft-tissue sarcoma
develop osteopetrosis due to the lack of osteoclasts, the re-of childhood. It displays skeletal muscle differentiation but is
sorbing cell type of bone (Grigoriadis et al., 1994; Johnsonconsidered to originate from a multipotential mesenchymal cell
et al., 1992; Wang et al., 1992). Consistent with its originaltype. Rhabdomyosarcomas occur most often in the head and
identification as the transforming activity of the mouse osteosar-neck region, including the orbita, and are classified histologically
coma viruses FBJ-MuSV and FBR-MuSV (Finkel et al., 1966),as embryonal, alveolar, and pleomorphic. In humans, the most
ectopic expression of Fos in embryonal stem cells and trans-consistent genetic alterations correlating with rhabdomyosar-
genic mice results in oncogenic transformation and the develop-coma development of the alveolar subtype are t(2;13)(q35;q14)
ment of chondrosarcoma and osteosarcoma, respectively (Gri-and t(1;13)(p36;q14) translocations, which result in overexpres-
goriadis et al., 1993; Wang et al., 1991). In addition, Fossion of chimeric PAX3-Forkhead (PAX3-FKHR) and PAX7-FKHR
mediates both pro- and antiapoptotic signals and regulatestranscription factors (Barr et al., 1993; Davis et al., 1994; Galili
invasive growth and angiogenesis during tumorigenesis (Hafeziet al., 1993). PAX-FKHR fusion proteins enhance tumor cell
et al., 1997; Orlandini et al., 1996; Saez et al., 1995; Schreiber
proliferation and invasive growth (Anderson et al., 2001; Ayyana-
et al., 1995). In contrast to the prototype Fos protooncogene,
than et al., 2000; Bernasconi et al., 1996) and protect tumor Trp53 prevents oncogenic transformation by blocking cell cycle
cells against apoptosis, most likely by inducing BCL-XL (Margue progression or inducing apoptosis (Levine, 1997). Trp53 is fre-
et al., 2000), c-MET (Epstein et al., 1996; Ginsberg et al., 1998), quently mutated in human tumors, and Trp53-deficient mice
and other regulators of myogenic differentiation (Khan et al., develop a wide spectrum of malignancies with a high predisposi-
1998, 1999). In addition, many human rhabdomyosarcomas tion toward lymphomas (Harvey et al., 1993; Jacks et al., 1994).
overexpress survival factors, such as IGF2, and carry mutations
in the TP53 tumor suppressor gene and in other cell cycle Results
regulators such as MDM2, CDKN2A (p16INK4), and CDK4 (Merlino
and Helman, 1999). To study a possible genetic interaction between germline muta-
tions in the Trp53 and Fos genes, Trp53/ and Fos/ miceThe Fos protein is a major component of the AP-1 transcrip-
S I G N I F I C A N C E
Rhabdomyosarcoma is the most common soft-tissue sarcoma in children, yet little is known about the underlying genetic changes
causing this disease. Trp53/Fos double knockout mice provide an important mouse model for rhabdomyosarcoma. Several aspects
of human rhabdomyosarcoma development, such as a short latency period, localization of tumors to the head and neck region,
and histological and immunohistochemical characteristics, are faithfully recapitulated in Trp53/Fos mutant mice. This study identifies
a novel and unexpected tumor suppressive function of the Fos protooncogene.
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Figure 1. Rhabdomyosarcoma development in Trp53/Fos mutant mice
Rhabdomyosarcoma incidence was analyzed in Trp53/;Fos/ (n  29)
and Trp53/;Fos/ mice (n  20) in comparison to Trp53/;Fos/ controls
(n 20). Trp53/;Fos/ mice develop rhabdomyosarcomas with high pen-
etrance and short latency. Rhabdomyosarcomas were observed in
Trp53/;Fos/ with lower penetrance but never developed in Trp53/;
Fos/ mice.
were intercrossed to generate Trp53/Fos double mutant mice.
These compound mice were obtained at Mendelian numbers
and initially were phenotypically indistinguishable from the os-
teopetrotic Fos/ mice (data not shown). However, Trp53/;
Fos/ mice started to develop tumors of the facial and orbital
regions at 10 weeks of age, and tumor penetrance was 93%
at 25 weeks (Figure 1). Tumors at these sites also grew in
Trp53/;Fos/mice, although with lower penetrance, but were
Figure 2. Histology of rhabdomyosarcomas and muscle tissue in p53/Fosnot observed in Trp53/;Fos/ and Trp53/;Fos/mice (Fig-
mutant miceure 1, data not shown). Histological analyses of tumors revealed
Histological analyses of a tumor derived from the orbita of a Trp53/;Fos/broad anastomosing fascicles of tumor cells with small areas
mouse reveals a spindle cell sarcoma (A) with areas of necrosis ([B]; noteof necrosis (Figures 2A and 2B). Tumor cells were polygonal or
asterisk), nuclear pleomorphism ([C]; arrow), high Ki-67 labeling index ([D];elongated and had pleomorphic nuclei and abundant eosino- arrows), and nuclear immunoreactivity for rhabdomyoblastic markers,
philic cytoplasm with cross-striations (Figure 2C). Mitotic figures MyoD ([E]; arrows), and myogenin ([F]; arrows). Muscle tissue from the orbita
of a Trp53/;Fos/ mouse (H) shows no abnormalities compared to anwere numerous, and staining for the cell cycle-associated Ki-67
age-matched Trp53/;Fos/ control (G). Magnification is 90 in A, 180antigen revealed high proliferative activity (Figure 2D). Tumors
in B, 220 in C–F, and 110 in G and H.displayed invasive growth into facial and external orbital mus-
cles, suggesting an origin in the muscle compartments of these
sites. Immunoreactivity for well-established markers of myo-
genic differentiation, including desmin (data not shown), myo- under appropriate conditions, cells fused to form differentiated
genin, and MyoD, was observed in most tumor cells (Figures myotubes with cytoplasmic cross-striations, providing addi-
2E and 2F). Tumor cell morphology and marker profile were tional evidence for the rhabdomyoblastic phenotype of the tu-
remarkably similar to the embryonal type of human rhabdomyo- mor cells (Figure 3B). We next analyzed the effects of reexpress-
sarcoma. To analyze whether inactivation of the Trp53 and Fos ing Fos and Trp53 in double mutant cell lines using retroviral
genes interferes with normal muscle development, histological gene transfer. Expression of Trp53 resulted in massive cell
analysis of orbital and femoral muscles was performed in 6- to death, and no cell lines could be established (data not shown).
10-week-old, tumor-free Trp53/;Fos/mice. No morphologi- This is in agreement with Trp53 function to induce cell cycle
cal abnormalities were found, and comparable numbers of satel- arrest and apoptosis when overexpressed in cultured cells (Diller
lite cells and Ki-67-reactive cells were present in muscles de- et al., 1990). In contrast, we were able to generate Trp53/;
rived from Trp53/;Fos/ and Trp53/;Fos/ mice (Figures Fos/ rhabdomyosarcoma cell lines reexpressing Fos as
2G and 2H, data not shown). Therefore, muscle tumor develop- judged by RNase protection and Western blot analysis (Figure
ment in Trp53/Fos mutant mice is not associated with a general 4A and data not shown). Fos reexpression in rhabdomyosar-
defect in muscle cell differentiation and increased numbers of coma cell lines did not alter cellular morphology. However, cell
progenitor cells. lines expressing Fos grew significantly slower than noninfected
To study the cellular mechanisms underlying muscle tumor or empty-vector controls, resulting in 30%–60% fewer cells
development, tumor cell lines were established. They all showed after 6 days in culture (Figure 3C). Therefore, we next analyzed
characteristic myoblast morphology and expressed the muscle- potential effects of Fos reexpression on proliferation and cell
death. Whereas cell cycle analysis by flow cytometry did notspecific markers MyoD and desmin (Figure 3A). When grown
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cient rhabdomyosarcoma cells leads to increased cell death
without affecting cell proliferation.
To begin to understand the molecular pathways responsible
for the apoptosis in Trp53/Fos mutant rhabdomyosarcoma cell
lines after ectopic Fos expression, we analyzed mRNA levels
of other AP-1 genes and genes known to modulate apoptosis
in rhabdomyosarcoma cells, including Pax genes. RNase pro-
tection assays revealed that reexpression of Fos did not change
mRNA levels of other AP-1 family members in all three rhabdo-
myosarcoma cell lines tested, except for Fosl1 (Fra-1), which
has previously been shown to be a transcriptional target of Fos
(Bergers et al., 1995) (Figure 4A). Expression of Bcl-2 family
members and death signaling molecules of the TNF- and Fas
pathways were also not significantly affected by ectopic Fos
expression (Figure 4B). However, expression of Pax7 was sub-
stantially repressed by Fos in two of three cell lines analyzed
(Figure 4C and data not shown). Expression of the other Pax
genes was not significantly changed.
Since Pax7 expression is downregulated during myogenic
terminal differentiation (Seale et al., 2000), we tested whether
Figure 3. Fos-induced apoptosis in rhabdomyosarcoma cell lines ectopic Fos expression would induce differentiation in rhabdo-
A: Indirect immunofluorescence analysis of rhabdomyosarcoma cell lines myosarcoma cell lines. Semiquantitative and quantitative RT-
established from Trp53/Fos-deficient muscle tumors. Under nondifferentiat- PCR analysis of myogenic marker gene expression revealeding conditions, cells express the muscle-specific markers MyoD (red, nuclear)
that Fos reexpression resulted in decreased levels of MyoD,and desmin (green, cytoplasmic).
B: Formation of myotubes with cross-striations visualized by -actinin staining Myogenin, and myosin heavy chain (MHC) IIb (Figures 5A and
in the cultures when grown at high density and in low serum medium. 5B). Moreover, Fos reexpression inhibited differentiation into
C and D: Reexpression of Fos in Trp53/Fos-deficient rhabdomyosarcoma mature myotubes (data not shown). These observations are
cell lines leads to reduced cell numbers (C) and increased spontaneous
consistent with published data identifying Fos/AP-1 as a nega-apoptosis (D) of tumor cells.
tive regulator of MyoD expression and myoblast differentiation
(Pedraza-Alva et al., 1994).
Finally, we tested whether ectopic Fos expression in primary
reveal significant changes in cell cycle progression (data not myoblasts would cause changes in gene expression similar to
shown), we found a 2- to 3-fold increase in the number of those observed in rhabdomyosarcoma cell lines. Primary myo-
apoptotic cells upon ectopic Fos expression (Figure 3D). These blast cultures were prepared from Trp53-deficient newborn
data demonstrate that reexpression of Fos in Trp53/Fos-defi- mice, transfected with a Fos expression vector, and mRNA
was analyzed by quantitative RT-PCR. Ectopic Fos expression
resulted in upregulation of Mmp3 expression, a known Fos tar-
get gene (data not shown). Fos expression led to a decrease
in MyoD and Myogenin expression and, importantly, a decrease
in Pax7 expression below the detection limit (Figure 5C). These
data confirm that Fos negatively modulates the expression of
myogenic markers and show that Fos can repress Pax7 expres-
sion both in primary myoblasts and rhabdomyosarcoma cell
lines.
Discussion
This study shows that inactivation of the bona fide oncogene
Fos in Trp53 mutant mice specifically leads to the formation of
sarcomas that morphologically resemble the embryonal variant
of human rhabdomyosarcoma. In humans, most rhabdomyosar-
comas of this type localize to the head and neck region, where
rhabdomyosarcoma development consistently occurs in Trp53/
Fos mutant mice. The mechanism for this selective localization
to the face and orbita, both in human and mouse, remains
unexplained. Reexpression of Fos in Trp53/Fos mutant rhabdo-
myosarcoma cell lines did not alter cell cycle progression but led
to increased cell death of tumor cells, suggesting that impairedFigure 4. Fos is able to downregulate Pax7 in rhabomyosarcoma cell lines
apoptosis contributes to rhabdomyosarcoma formation in
mRNA expression levels of AP-1 family members (A), of genes that modulate
Trp53/Fos mutant mice. The increase in apoptosis upon Fosapoptosis (B), and of Pax genes (C) were analyzed by RNase protection
assay after mock transfection or reexpression of Fos. reexpression is consistent with previous observations that Fos
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rare, and the application of most models is limited by low tumor
penetrance or long latency (Hahn et al., 1998; Harvey et al.,
1993; Takayama et al., 1997; Teitz et al., 1993; Vogel et al.,
1999). Since rhabdomyosarcoma development in Trp53/Fos
mutant mice is frequent and similar to tumorigenesis in mice
carrying a hepatocyte growth factor/scatter factor (HGF/SF)
transgene in an Ink4a/Arf-deficient background (Sharp et al.,
2002) and in mice carrying a HER-2/neu transgene in a Trp53
mutant background (Nanni et al., 2003), these mutant mice may
provide unique models for therapeutic studies. Moreover, the
rhabdomyosarcomas in Trp53/Fos mutant mice closely resem-
ble human rhabdomyosarcoma with respect to location and
histology; therefore, we speculate that Fos inactivation might
also play a role in human rhabdomyosarcoma development.
Experimental procedures
Mice and histological analysis
Generation, genotyping, and phenotypic characterization of Trp53 and Fos
mutant mouse strains have been decribed previously (Jacks et al., 1994;
Wang et al., 1992). Mutant mice were maintained on a mixed (129Sv x
C57BL/6) genetic background. Tissues were immersion fixed in 4% buffered
formalin, embedded in paraffin, sectioned, and stained with haematoxylin/
eosin using standard histological techniques. For immunohistochemistry,
antigen retrieval with citrate buffer was performed, and tissue sections were
incubated with primary antibody: desmin (clone Y-20; Santa Cruz), MyoD
(clone 5.8A; DAKO), myogenin (F5D; DAKO), Ki-67 (clone TEC3; DAKO).
Immunoreactivity was detected with biotinylated secondary antibodies and
the biotin/streptavidin-horseradish peroxidase system (DAKO; Vector) using
diaminobenzidine (DAB) as a chromogen.
Generation of rhabdomyosarcoma cell lines and primary
myoblasts, immunofluorescence staining
Figure 5. Effects of ectopic Fos expression on myogenic marker gene and Tumor samples were mechanically disaggregated and explanted into petri
Pax7 expression in rhabomyosarcoma cell lines and primary myoblasts dishes. Pools of cells from three independently isolated tumors were estab-
lished as cell lines and further characterized. Experiments were performedExpression analysis of myogenic marker genes in Trp53/Fos-deficient rhab-
at passage 5–8 in culture. For all experiments, cells were cultured in DMEMdomyosarcoma cell lines upon reexpression of Fos. RNA expression levels
were analyzed by semiquantitative (A) and quantitative (B) RT-PCR. For A containing 10% fetal calf serum, except for differentiation into myotubes,
and B, a representative example of data obtained from three independent which was performed in DMEM containing 5% horse serum. Indirect immu-
cell lines is shown. C: Expression analysis of myogenic marker genes in Trp53- nofluorescence staining of cells was performed according to standard tech-
deficient primary myoblasts upon ectopic expression of Fos. Cells were niques using the following primary antibodies: desmin (clone Y-20; Santa
transfected with pBabe control or Fos expressing vector, and RNA expression Cruz), MyoD (clone 5.8A; DAKO), and -actinin (Sigma). Primary myoblasts
levels were analyzed by quantitative RT-PCR. were prepared from newborn Trp53/ mice (Springer et al., 1997).
Retroviral gene transfer, proliferation, and apoptosis assays
Fos and Trp53 cDNAs were cloned into pBabe retroviral vectors containing
an IRES-EGFP cassette to monitor expression. Tumor cell lines at passagecan have proapoptotic functions in various cell types, including
6 were infected with viruses and selected with 2.5 ug/ml Puromycin ac-neurons, retinal photoreceptors, prostatic epithelial cells, and
cording to standard procedures. Expression of Fos and Trp53 was verifiedB lymphocytes (Jochum et al., 2001). Ectopic expression of Fos
by Northern blot and Western blot analysis. For proliferation assays, 0.3 
was associated with a substantial reduction of Pax7 expression 105 cells were plated into 6-well dishes and counted every 24 hr for 6
in primary myoblasts and in two of three Trp53/Fos mutant consecutive days. Duplicates were counted for each cell line and time point.
rhabdomyosarcoma cell lines. Pax7 has previously been shown For apoptosis assays, cells were plated in duplicates at 0.5  105 cells per
6-well dish, and apoptosis was measured after 48 hr in culture using theto be essential for the differentiation of myogenic satellite cells
Annexin-V cell death detection kit (Roche) according to the manufacturer’s(Seale et al., 2000), and elevated Pax7 levels have been found
instructions. Primary myoblasts were transfected with either pBabe controlin a human embryonal rhabdomyosarcoma cell line (Bernasconi
or Fos expressing vector with Lipofectamine according to the manufacturer’s
et al., 1996). Moreover, treatment of this rhabdomyosarcoma recommended protocol.
cell line with Pax7 antisense oligonucleotides induced cell death
(Bernasconi et al., 1996). These data suggest that reduced Pax7 RNase protection assay, quantitative RT-PCR
Total RNA was isolated with the TRIZOL protocol (Sigma). RNase protectionlevels could account for the increased apoptosis after reexpres-
assays were performed using the RiboQuant multiprobe RNase protectionsion of Fos. However, altered Pax7 expression was observed
assay systems mJun/Fos, mApo-2, mApo-3, and mPax (Pharmingen) ac-in only two of three Trp53/Fos mutant rhabdomyosarcoma cell
cording to the manufacturer’s protocol. Expression of myogenic markerslines. Future experiments using cDNA microarray analysis will
and controls were analyzed by real-time PCR using DNA Engine Opticon 2
aim to unravel additional mechanisms involved in Fos-depen- Lightcycler with the following primers. Hprt Forward GCTTGCTGGTGA
dent rhabdomyosarcoma development. AAAGGACCTC; Hprt Reverse CAAATCAAAAGTCTGGGGACGC; Tubulin
Forward CAACGTCAAGACGGCCGTGTG; Tubulin Reverse GACAGAGGGenetically engineered models for rhabdomyosarcoma are
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